Trials / Terminated
TerminatedNCT04614051
Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)
An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Pharmicell Co., Ltd. · Industry
- Sex
- Female
- Age
- 19 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1 study to evaluate the safety of cancer immunotherapy with autologous dendritic cells in patients with advanced or recurrent epithelial ovarian cancer
Detailed description
To evaluate the safety of an autologous dendritic cell(DC) anticancer immune cell therapy (Cellgram-DC) for the treatment of advanced or recurrent epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cellgram-DC | Patients will receive 3 times every 2 weeks injection of Cellgram-DC(Autologous dendritic cell) subcutaneous injection near the upper arm lymph nodes |
Timeline
- Start date
- 2021-03-30
- Primary completion
- 2022-05-10
- Completion
- 2022-05-10
- First posted
- 2020-11-03
- Last updated
- 2023-01-03
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04614051. Inclusion in this directory is not an endorsement.